Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

ADT-AAP combo effective for mHNPC independent of risk stratification

20 Nov 2019

The combination of androgen deprivation therapy (ADT) with abiraterone acetate and prednisolone (AAP) treatment is effective against metastatic hormone-naïve prostate cancer (mHNPC) regardless of risk stratification, a recent study has shown.

Researchers performed a posthoc subgroup analysis of the STAMPEDE trial, including 901 participants, of whom 428 were defined as low-risk, while the remaining 473 were high-risk. The primary outcome was overall survival (OS), while secondary outcome was failure-free survival (FFS).

In the low-risk criteria, 220 received ADT alone, while 208 were treated with both ADT and AAP. In the high-risk group, 232 received monotreatment while 241 received the combination therapy.

A total of 330 deaths were reported. Absolute 3-year survival rates were significantly better in low-risk patients given the combination therapy (83 percent vs 78 percent; hazard ratio [HR], 0.66, 95 percent confidence intervals [CI], 0.44–0.98). The same was true for the high-risk group (65 percent vs 45 percent; HR, 0.54, 95 percent CI, 0.41–0.70).

Similar effects were reported for the secondary outcomes. In low-risk patients, 3-year FFS showed a 44-percent absolute improvement after ADT+AAP relative to ADT alone (76 percent vs 32 percent; HR, 0.25, 95 percent CI, 0.17–0.33). The magnitude of difference decreased in high-risk patients, but nevertheless remained significant (45 percent vs 12 percent; HR, 0.31, 95 percent CI, 0.25–0.39).

The present findings support the use of ADT and AAP for mHNPC independent of risk stratification, said the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.